GRAIL, LLC Q3 2025 Earnings Recap

GRAL Q3 2025 November 13, 2025

Get alerts when GRAL reports next quarter

GRAIL reported strong third-quarter performance, with a 39% increase in Gallery volume and a 29% increase in revenue year-over-year, reflecting robust uptake and strategic developments in key markets.

Earnings Per Share Beat

$-2.46 vs $-3.36 est.

+26.8% surprise

Revenue Beat

36194000 vs 34598633 est.

+4.6% surprise

Market Reaction

1-Day -1.85%

5-Day -3.9%

30-Day +17.73%

See GRAL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Gallery tests are growing in adoption, with approximately 420,000 tests sold across over 16,000 healthcare providers.
Strategic collaboration announced with Samsung to commercialize Gallery in South Korea and other Asian markets, alongside a $110 million equity investment from Samsung.
Successfully launched Gallery in Canada through a partnership with MedCan, expanding market presence.
Completed a $325 million private placement to strengthen financial position as the company progresses towards key milestones.
Positive results from PATHFINDER II study showcased substantial cancer detection improvements, underscoring Gallery’s effectiveness in early cancer diagnosis.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GRAL on AllInvestView.